title: Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals.
abstract: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia for which therapeutic options remain unsatisfying as cure has remained elusive. Recent laboratory discoveries and promising results from completed phase III studies with fludarabine provide reason to reassess therapeutic goals in the treatment of patients with symptomatic CLL. Early enrollment of patients on protocols using combination therapies with fludarabine and new agents such as flavopiridol, IDEC-C2B8, Campath-1H, UCN-01, bryostatin, FR 901228, and melarsoprol will hopefully represent the next advance to improved overall survival and ultimately the cure of CLL.
authors.affiliation: Hematology-Oncology Service, Walter Reed Army Medical Center, Washington, DC 20307, USA.
authors.forename: J C
authors.initials: JC
authors.lastname: Byrd
authors.forename: K R
authors.initials: KR
authors.lastname: Rai
authors.forename: E A
authors.initials: EA
authors.lastname: Sausville
authors.forename: M R
authors.initials: MR
authors.lastname: Grever
mesh_terms: D000470:Alkaloids / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D054713:Bryostatins; D005419:Flavonoids / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D018942:Macrolides; D010880:Piperidines / Q000627:therapeutic use; D019311:Staurosporine / Q000031:analogs & derivatives; D059004:Topoisomerase I Inhibitors
chemical_list: D000470:Alkaloids; D018906:Antineoplastic Agents, Alkylating; D054713:Bryostatins; D005419:Flavonoids; D007783:Lactones; D018942:Macrolides; D010880:Piperidines; D059004:Topoisomerase I Inhibitors; C046785:bryostatin 1; C077990:alvocidib; C054852:7-hydroxystaurosporine; D019311:Staurosporine